OncoMatch/Clinical Trials/NCT06357182
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Is NCT06357182 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Azacitidine and Iadademstat for acute myeloid leukemia.
Treatment: Azacitidine · Iadademstat · Venetoclax — This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell growth in LSD1-overexpressing cancer cells. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving iadademstat with azacitidine and venetoclax may be safe, tolerable and/or effective in treating patients with newly diagnosed AML who cannot undergo intensive chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Excluded: ABL1 bcr::abl1 fusion
AML with BCR::ABL1 fusions will be excluded
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: LSD1/KDM1A inhibitor
Treatments targeting or inhibiting LSD1/KDM1A within 12 months prior to the start of IADA
Cannot have received: BCL2 inhibitor
Treatments targeting or inhibiting BCL 2 within 12 months prior to the start of IADA
Lab requirements
Blood counts
White blood cell (WBC) < 20 x 10^9/L prior to study start
Kidney function
Creatinine clearance (CrCl) of ≥ 60 mL/min (patients ≥ 75 years); CrCl ≥ 30 mL/min to < 45 ml/min (patients 18–74 years with comorbidity)
Liver function
Total bilirubin ≤ 1.5 x ULN (patients ≥ 75 years); moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × ULN (patients 18–74 years with comorbidity); AST/ALT ≤ 2.0 x institutional ULN
Total bilirubin ≤ 1.5 x ULN (patients ≥ 75 years); moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × ULN (patients 18–74 years with comorbidity); AST/ALT ≤ 2.0 x institutional ULN; Creatinine clearance (CrCl) of ≥ 60 mL/min (patients ≥ 75 years); CrCl ≥ 30 mL/min to < 45 ml/min (patients 18–74 years with comorbidity); White blood cell (WBC) < 20 x 10^9/L prior to study start
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OHSU Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06357182 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with ABL1 alterations eligible?
No. ABL1 bcr::abl1 fusion is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify